Activated clotting time (ACT)-guided intravenous dalteparin dosing during percutaneous coronary intervention.
نویسندگان
چکیده
BACKGROUND The activated clotting time (ACT) has been reported to be sensitive to the anticoagulant activity of the low-molecular weight heparin dalteparin following intravenous (IV) administration. OBJECTIVE To evaluate the feasibility of an ACT-guided dalteparin dose adjustment strategy during percutaneous coronary intervention (PCI). METHODS This was a retrospective study of 104 consecutive patients who underwent PCI using an ACT-guided strategy of IV dalteparin. All patients received an initial IV bolus of 50 IU/kg of dalteparin. The minimum target ACT was 175 seconds for patients who received glycoprotein IIb/IIIa inhibitors and 200 seconds for patients who did not. Patients who did not achieve the target ACT after the initial 50 IU/kg were given supplemental boluses of dalteparin based on the assumption that for every additional 10 IU/kg of dalteparin, the ACT will rise by approximately 10 seconds. RESULTS After the initial bolus of dalteparin, the mean baseline ACT rose from 138 +/- 41 seconds to 235 +/- 78 seconds. In the 36 patients (35% of the study population) who required a mean supplemental dose of 14 +/- 6 IU/kg/kg, the mean ACT after the supplemental dose was 239 +/- 79 seconds. The composite endpoint of in-hospital death, target vessel revascularization (TVR) and myocardial infarction (MI) was 5.8%. Major and minor bleeding rates were 1% each. The composite incidence of death/MI/TVR was comparable to, and the bleeding complications were lower than, those achieved in the SYNERGY and STEEPLE trials. CONCLUSION ACT-guided dose adjustment of intravenously administered dalteparin during PCI appears to constitute a feasible strategy.
منابع مشابه
The activated clotting time (ACT) can be used to monitor enoxaparin and dalteparin after intravenous administration.
BACKGROUND The use of low-molecular weight heparin (LMWH) during percutaneous coronary intervention (PCI) has been limited by the presumed inability to monitor its anticoagulant effect using bedside assays. OBJECTIVES This study was designed to compare the dose-response of enoxaparin, dalteparin and unfractionated heparin (UFH) on the activated clotting time (ACT), and to determine whether th...
متن کاملThe activated clotting time can be used to monitor the low molecular weight heparin dalteparin after intravenous administration.
OBJECTIVES This study was designed to compare the dose response of dalteparin versus unfractionated heparin (UFH) on the activated clotting time (ACT), and to determine whether the ACT can be used to monitor intravenous (IV) dalteparin during percutaneous coronary intervention (PCI). BACKGROUND The use of low molecular weight heparin (LMWH) during PCI has been limited by the presumed inabilit...
متن کاملEvaluation of bivalirudin hyper- and hypo-ACT responses in the setting of percutaneous coronary intervention.
BACKGROUND Bivalirudin has emerged as a suitable alternative anticoagulant to unfractionated heparin and low-molecular-weight heparins during percutaneous coronary intervention (PCI) procedures in the management of coronary artery disease and acute coronary syndromes (ACS). In clinical trials, bivalirudin dosing was standardized, and activated clotting time (ACT) did not influence dosing adjust...
متن کاملMethods and Results—In the Fondaparinux With Unfractionated Heparin During Revascularization in Acute Coronary Syndromes
Periprocedural anticoagulation is recommended during percutaneous coronary intervention (PCI) to prevent thrombus forming on the wires, balloon, and catheters. Unfractionated heparin (UFH) remains widely used in this indication (≈60% of patients with non–ST-segment–elevation myocardial infarction [NSTEMI] undergoing PCI in the United States received UFH, according to data from the recent Nation...
متن کاملActivated Clotting Time Level with Weight Based Heparin Dosing During Percutaneous Coronary Intervention and its Determinant Factors
INTRODUCTION Percutaneous coronary intervention (PCI) may be associated with Thrombotic complications. Unfractionated heparin (UFH) is a potent and preferable antithrombotic agent during this procedure. Activated clotting time (ACT) is a good assay for accurate titration of UFH during PCI. The aim of this study was to evaluate ACT levels 10 minutes after administration of 100U/kg IV heparin and...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- The Journal of invasive cardiology
دوره 20 7 شماره
صفحات -
تاریخ انتشار 2008